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Abstract

Author Manuscript

BACKGROUND—Hypothetically, delay between melanoma diagnosis and SLNB could affect
outcomes, either adversely by allowing growth and dissemination of metastases, or beneficially by
allowing development of an anti-melanoma immune response. Available data are conflicting about
the effect of SLNB delay on patient survival. Our objective was to determine whether delay
between initial diagnosis and SLNB affects outcomes in patients with cutaneous melanoma.
STUDY DESIGN—We performed query and analysis of a large prospectively maintained
database of patients with primary cutaneous melanomas undergoing SLNB. An independent
dataset from MSLT-1 (Multicenter Selective Lymphadenectomy Trial-1) was used for validation.
Primary outcomes included disease-free survival and melanoma-specific survival.
RESULTS—Early and delayed SLNB were defined as less than 30 and 30 or more days from
initial diagnosis, respectively. There were 2,483 patients that met inclusion criteria. Positive
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sentinel lymph nodes were identified in 17.4% (n = 432). Among all patients, 42% had SLNB 30
or more days after diagnosis and 37% of positive sentinel lymph nodes were at 30 or more days.
No differences in sex, anatomic site, or histopathologic features were identified between the 2
groups. There was no difference in melanoma-specific survival or disease-free survival between
those undergoing early or delayed SLNB. Examination of MSLT-1 trial data similarly
demonstrated no difference in survival outcomes.
CONCLUSIONS—This, the largest study on this subject to date, found no adverse impact on
long-term clinical outcomes of patients due to delay of SLNB beyond 30 days. The MSLT-1 data
confirm this result. Patients can be reassured that if the operation is performed 30 or more days
after diagnosis, it will not cause harm.
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More than 25 years ago, Drs Morton and Cochran pioneered lymphatic mapping and SLNB
in the management of cutaneous melanoma.1 Since its introduction, a large body of research
has been generated not only validating the use and accuracy of the technique,2,3 but also
demonstrating that early treatment of nodal metastases leads to substantial improvements in
patient outcomes, including prolonged distant disease-free survival (DFS) and melanomaspecific survival (MSS).4 In addition, extensive data have accumulated supporting the notion
that the status of the sentinel node is the single most important prognostic factor for patients
with early cutaneous melanoma.4,5
Based on the predictable and orderly manner in which melanoma spreads,6 it would seem
intuitive that expeditious definitive surgical management (wide local excision and SLNB)
after initial diagnosis of a cutaneous melanoma would be advantageous. However, existing
outcomes data on the effect of delaying initial surgical treatment are mixed and
contradictory.7–11
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Hypothetically, a delay between melanoma diagnosis and SLNB could affect outcomes,
either adversely by allowing growth and dissemination of metastases, or beneficially by
allowing development of an anti-melanoma immune response.8,11 Currently, existing data on
the effect of SLNB delay on patient survival are conflicting. Therefore, our objective was to
determine whether modest delay between diagnosis and SLNB affects outcomes in patients
with cutaneous melanoma.

METHODS
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This study received IRB-exemption status after independent regulatory review. We queried
our prospectively maintained database (July 1, 1991 through July 1, 2015) for all patients
diagnosed with clinical stage I or II cutaneous melanoma and subsequently received wide
local excision and SLNB.12 Date of diagnosis was the date of cutaneous biopsy. To lessen
any impact of referral bias, analysis was limited to patients definitively treated at our
institution within 6 months of initial diagnosis. Patients with more than 1 primary melanoma
were excluded, as were patients with early recurrence—within 90 days of wide local
excision and SLNB—as this was considered concurrent disease, clinically inapparent at the
time of initial treatment.
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Patients were stratified into 2 groups: early and delayed SLNB. Previous series have
examined delay times with cutoffs varying among 30, 40, 43, and 47 days, which reflected
median “delay” before surgery for the respective study populations in those series.7–11 Initial
exploratory analysis of our cohort revealed a median delay from initial diagnosis to
definitive wide local excision and SLNB of 27 days (mean 31.8 days; range 0 to 182 days).
Stratified by 30-day intervals, 57.9% (n = 1,437) underwent SLNB less than 30 days from
the time of initial diagnosis, 34.7% (n = 861) between 30 and 59 days, 4.8% (n = 120)
between 60 and 89 days, and 2.6% (n = 65) at 90 days or more from the time of initial
diagnosis. Based on these findings, as well as cutoffs examined in the literature previously,
we defined early SLNB as occurring less than 30 days after initial cutaneous biopsy and
delayed SLNB as occurring 30 or more days from initial diagnosis.
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Treatment comprised wide local excision with excision margins determined by current
recommendations, as well as SLNB, if indicated by the histopathology of the excision
biopsy specimen. Technical details of performance of SLNB at the John Wayne Cancer
Institute have been described previously.13 Clinical follow-up consisted of complete
dermatologic and physical examination every 3 months during the first 2 years and every 4
to 6 months for the next 3 years, then annually thereafter. Routine tests, including complete
blood count, comprehensive metabolic panel, lactate dehydrogenase, and radiographic
imaging, were obtained annually when indicated by pathologic stage.
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Clinical factors, including age, sex, and anatomic site of the primary lesion, as well as
histopathologic features, such as Breslow thickness; mitotic rate; presence of ulceration; and
lymph node status, were compared between patients in the early and delayed treatment
groups. Categorical variables were compared using chi-square test. For comparison of
means, t-test or Wilcoxon rank-sum test were used where appropriate. Disease-free survival
and MSS curves were generated using the Kaplan-Meier method and comparisons made
using the log-rank test. Common prognostic variables and delay times were then included in
multivariable analysis using Cox proportional hazards model to identify significant
independent predictors of DFS and MSS.
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To validate these findings, identical analyses were performed using an independent dataset
from the SLNB arm of the first Multicenter Selective Lymphadenectomy Trial (MSLT-1), a
multi-institutional prospective randomized trial.4 The same cut point of 30 days was used in
this analysis. Exploratory analysis of the MSLT-1 cohort revealed a median delay time from
initial diagnosis to definitive wide local excision and SLNB of 29 days (mean 33.8 days;
range 0 to 103 days). Stratified by 30-day intervals, 53.7% (n = 626) underwent SLNB less
than 30 days from the time of initial diagnosis, 35.2% (n = 410) between 30 and 59 days,
10.6% (n = 123) between 60 and 89 days, and 0.5% (n = 6) more than 90 days from the time
of initial diagnosis.
All statistical analyses were performed using SAS software, version 9.3 (SAS Institute) and
p values < 0.05 were considered significant.
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RESULTS
From July 1, 1991 to July 1, 2015, a total of 2,483 patients underwent wide local excision
and SLNB for primary cutaneous melanoma. Median follow-up was 8 years (95.7 months).
Median times to surgery for the early and delayed SLNB groups were 21 and 41 days,
respectively. A majority of patients underwent early SLNB (58%).
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Baseline demographics and histopathologic characteristics for the 2 groups are compared in
Table 1. On univariate analysis, delayed SLNB patients were significantly older (56.3 vs
54.7 years; p = 0.02). There were no differences in sex, anatomic site of the primary lesion,
or histopathologic features of the primary lesion between the 2 groups (all p > 0.05).
However, patients with delayed SLNB had a lower frequency of sentinel lymph node
positivity (15.1% vs 19.1%; p = 0.01). Despite differences in frequency of sentinel lymph
node positivity between the 2 groups, there was no significant difference in DFS or MSS
(Fig. 1A and B).
After adjusting for age, sex, Breslow thickness, presence of ulceration, and sentinel lymph
node status, multivariable analysis indicated that early vs delayed SLNB was not an
independent predictor of DFS (hazard ratio [HR] = 0.98; 95% CI 0.81 to 1.18; p = 0.85) or
MSS (HR = 1.05; 95% CI 0.83 to 1.34; p = 0.67) (Table 2). Age, Breslow thickness, and
presence of ulceration were independently associated with worse DFS and MSS (all p <
0.001). Positive sentinel lymph node status had the greatest prognostic significance of any
independent variable for both disease recurrence (HR = 3.07; 95% CI 2.50 to 3.77; p <
0.001) and MSS (HR = 3.11; 95% CI 2.40 to 4.03; p < 0.001).
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Because the status of the sentinel lymph node is of such profound prognostic significance,
subgroup analysis was undertaken to determine whether delay times specifically impacted
patients found to have positive sentinel nodes. Positive sentinel lymph nodes were identified
in 17.4% of patients (n = 432). Median times to wide local excision and SLNB were 26 and
28 days for patients with positive and negative sentinel lymph nodes, respectively (mean
30.7 and 32.1 days, respectively; p = 0.003). Of those patients with positive sentinel nodes,
37% (n = 158) had undergone delayed SLNB. No differences in age, sex, anatomic site, or
histopathologic characteristics were noted between the 2 groups (all p > 0.05) (Table 3). No
differences in DFS or MSS were identified between these groups (Fig. 1C and D).
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To validate these findings, a separate analysis was undertaken using prospective data
collected from the MSLT-1 trial. The same cutoff point of 30 days defined early and delayed
SLNB groups. This cohort included 1,165 patients, of which 46.3% underwent delayed
SLNB. Baseline demographics and histopathologic characteristics for the 2 groups are
compared in Table 1. Among MSLT-1 patients, those in the early SLNB group were more
frequently male, and primary lesions more commonly arose in the head/neck or trunk
regions relative to the delayed SLNB group (both p < 0.05). Positive sentinel lymph nodes
were identified in 19% (n = 221) of patients. Of note, contrary to the John Wayne Cancer
Institute database cohorts, patients undergoing delayed SLNB in MSLT-1 more frequently
had positive sentinel nodes than patients undergoing early SLNB (22.8% vs 15.6%; p =
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0.002). Again, however, despite the differences in sentinel lymph node positivity between
the 2 groups, there was no difference in DFS or MSS (Fig. 2A and B).
Among sentinel lymph node-positive patients, a slight majority (55.7%) had undergone
delayed SLNB (Table 3). This was not associated with any measurable difference in DFS or
MSS between the groups (Fig. 2C and D).
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Because delay in SLNB was associated with significant but opposite effects on SLN
positivity in the 2 study cohorts, we elected to perform multivariable logistic regression
analysis to determine whether delay time remained a significant prognostic indicator for
sentinel lymph node positivity. Recognized prognostic clinical and histopathologic factors
including age, sex, primary anatomic site, Breslow thickness, ulceration, and mitotic rate
were included in the model. In addition, delay time was included as a dichotomized variable
(Table 4). Commonalities between the 2 datasets included increasing Breslow thickness as
an independent predictor for sentinel lymph node positivity and increasing age and head/
neck and upper extremity locations compared with trunk primary location; all were
significantly associated with a decreased likelihood of having a positive sentinel node.
Interestingly, among patients in the John Wayne Cancer Institute dataset, delay time of less
than 30 days was independently associated with a 33% increased risk of sentinel lymph node
positivity (odds ratio = 1.33; 95% CI 1.05 to 1.67; p = 0.02). Conversely, among MSLT-1
patients, delay time of less than 30 days was independently associated with a 36% decreased
risk of having a positive sentinel lymph node (odds ratio = 0.64; 95% CI 0.47 to 0.88; p =
0.006).

DISCUSSION
Author Manuscript

Timely diagnosis of many cancers is associated with improved outcomes by identifying
lesions at their earliest and most treatable stages. This principle forms the foundation of
many successful screening programs. Conversely, delay in presentation, diagnosis, and/or
treatment of cancer has been linked to poor outcomes.14 For melanoma in particular, it has
been demonstrated that delayed initial presentation is associated with more advanced lesions
at diagnosis, with negative prognostic implications.15 The prognostic impact of subsequent
delays, such as between initial diagnosis and definitive surgical management, remains
unclear. Previous series examining delay between diagnostic biopsy and wide local excision
of the primary showed no impact from delays ranging from less than 14 days to more than
92 days on long-term outcomes.16 However, this series did not assess management of the
sentinel node.
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In cutaneous melanoma, the most important prognostic factor is sentinel lymph node
status17 and, therefore, definitive initial surgical management of intermediate thickness and
high-risk thin melanomas is wide local excision and SLNB.18 Modest delays can occur
between initial biopsy-based diagnosis of melanoma, referral for definitive surgical
management, and definitive wide local excision and SLNB. Such delays theoretically could
affect outcomes, either adversely by allowing growth and dissemination of metastases or
favorably by allowing development of an anti-melanoma immune responses.8,11
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At least 4 smaller series have explored this question and produced varied findings. In the
earliest series, Parrett and colleagues7 performed a retrospective analysis of 492 patients
diagnosed with cutaneous melanoma, with a median time to SLNB of 39.5 days. Based on
this, they stratified and compared patients by delay times of less than 40 days vs at least 40
days and found that delay time was not associated with any detrimental effect on DFS (p =
0.13) or overall survival (p = 0.14).7 Similarly, a series reported by the European
Organization for Research and Treatment of Cancer Melanoma Group, which included 1,015
sentinel lymph node-positive patients with a median time of 47 days from diagnosis to
definitive surgery, and demonstrated that “delay” time had no impact on 5-year MSS (p =
0.72) and was not an independent prognostic factor for MSS (p = .57).10
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A few studies have noted differences in outcomes based on the interval between diagnosis
and SLNB. In 2015, Tejera-Vaquerizo and colleagues8 published a much larger series
addressing this clinical question. The authors found that among 1,963 patients, early SLNB
(less than 40 days) was associated with a worse MSS (HR = 1.7; 95% CI 1.2 to 2.5; p =
0.007).8 On subgroup analysis, the impact of delay time on MSS remained significant only
for those with negative sentinel lymph nodes and absence of regression in the primary tumor.
The authors postulated that early excision and SLNB can negatively affect development of
anti-melanoma immunity. Conversely, in a recent series by Fortes and colleagues,11 in which
748 patients with cutaneous melanoma underwent wide local excision and SLNB, the
authors found that for patients with positive sentinel lymph nodes, delay times of less than
30 days were associated with a 3-fold decreased risk of melanoma mortality compared with
patients with positive sentinel nodes whose surgery had been delayed more than 30 days.11
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In the current study of nearly 2,500 patients who had wide local excision and SLNB at the
John Wayne Cancer Institute in recent decades, we found no impact on disease recurrence or
MSS that could be attributed to early (less than 30 days) or delayed (30 days or more)
SLNB. In addition, such delays did not produce any measurable effect on the DFS or MSS
of even those patients found to have positive sentinel nodes at the time of surgery. These
results are in keeping with those of Parrett and colleagues7 and Oude Ophuis and
colleagues.10 Our findings are validated using data from the multinational, prospective
MSLT-1 dataset, where delays of less than 30 vs 30 or more days between time of initial
diagnosis and definitive surgery had no impact on DFS or MSS in all patients, with and
without positive sentinel nodes.
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Interestingly, we found that delay in SLNB was associated with significant, but opposite
effects on SLN positivity in the 2 study cohorts. Among patients in the John Wayne Cancer
Institute dataset, delay time of less than 30 days was independently associated with a 33%
increased risk of sentinel lymph node positivity, and for MSLT-1 patients, delay time of less
than 30 days was independently associated with a 36% decreased risk of having a positive
sentinel lymph node. A clear explanation for this finding is not evident based on the data.
The delayed cohort from the John Wayne Cancer Institute dataset was significantly older
compared with the corresponding early SLNB group (56.3 vs 54.7 years; p = 0.02).
Comparatively, the early and delayed SLNB groups from MSLT-1 were similar in age (p =
0.21). There is some evidence to suggest that lymphatic function declines with age and
therefore could result in reduced nodal positivity rates in older individuals.19 This represents
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one possible explanation for the differences noted. Nodal positivity in both groups is
associated with reduced DFS and MSS. However, the data are clear that timing of the SLNB,
whether less than 30 or more than 30 days, does not independently impact outcomes.

Author Manuscript
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Although this is the largest study to date that addresses this key clinical question, there are
limitations that should be acknowledged. This was a retrospective study of prospectively
collected data and is therefore subject to the limitations of any dataset review, including
missing data and loss to follow-up. However, the results of this study were validated using
data from the MSLT-1 trial, a prospective, randomized controlled trial with complete
preoperative, perioperative, and long-term follow-up data. It is possible that a more clinically
relevant cutoff point exists that would be better than the 30-day cutoff used in this series.
Earlier series have explored delay times ranging between 30 and 47 days and, as in the
current study, these earlier studies selected delay times based on median time to surgery to
determine their respective cohorts. We also used a 40-day cutoff to stratify patients, and time
as a continuous variable but in both cases found no difference in DFS or MSS (data not
shown). In the current series, we focused on outcomes for all patients and sentinel nodepositive patients separately because intuitively the latter would be most likely to be impacted
by delay. However, because Tejera-Vaquerizo and colleagues8 reported worse MSS in
patients undergoing early SLNB (less than 30 days) who had a negative sentinel node, we
also performed analysis on our negative sentinel node patients and again found no
significant difference in DFS or MSS (data not shown). The John Wayne Cancer Institute is
a high-volume melanoma referral center, which could result in a component of referral bias
that selected for more advanced or challenging cases. We attempted to control for this by
including only referral patients who underwent SLNB within 6 months of their initial biopsy
and excluding patients with early (less than 90 days) disease recurrence. Patients with
multiple primary cutaneous melanomas were also excluded.
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Although the results of this study support the conclusion that a modest delay of 30 or more
days to SLNB (median of 41 days in the delayed SLNB group) does not appear to impact
prognosis negatively, we cannot determine a safe upper limit of delay time. In the current
study, we included patients who underwent SLNB no more than 6 months from the time of
initial diagnosis, however, few patients suffered such extreme delay. In MSLT-1, median
time to development of clinically relevant nodal disease in the wide local excision alone arm
was 19.2 months.4 This delay was associated with worse outcomes for node-positive
patients, indicating that there is a delay that would be excessive and allow preventable
progression. However, the range of delays encountered in routine practice appear to be safe.
Defining a fixed maximum time interval beyond the modest delay found to be safe in this
study seems to be unnecessary at this time. What is important is to be able to offer
reassurance and minimize the stress and anxiety that accompanies a new diagnosis of
melanoma. Up to 30% of patients diagnosed with melanoma will report clinically relevant
psychological distress20 and issues related to prognosis and fear of death are often cited as
sources for anxiety in these patients.21 Delays between time of diagnosis and definitive
surgical management are often inevitable. However, based on the results of this study,
patients can be reassured that if the procedure must be delayed, there is a margin of time
during which the efficacy of the operation is unlikely to be diminished.
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CONCLUSIONS
This study demonstrated that a delay to SLNB beyond 30 days after initial biopsy does not
adversely impact long-term clinical outcomes in cutaneous melanoma. Patients can be
reassured that should the operation occur more than 30 days from diagnosis, it will not affect
their overall prognosis. Expeditious definitive care should, however, always be the goal.
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Figure 1.

(A) Disease-free survival (DFS) and (B) melanoma-specific survival (MSS) for all patients
and (C) DFS and (D) MSS for sentinel lymph node-positive patients from John Wayne
Cancer Institute, stratified by delay between initial diagnosis and time of wide local excision
and SLNB. NA, not applicable.
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Figure 2.

(A) Disease-free survival (DFS) and (B) melanoma-specific survival (MSS) for all patients
and (C) DFS and (D) MSS for sentinel lymph node-positive patients from the SLNB arm of
Multicenter Selective Lymphadenectomy Trial-1, stratified by delay between initial
diagnosis and time of wide local excision and SLNB. NA, not applicable.
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